Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
WHO Pharmaceuticals Newsletter 2005, No. 05
(2005; 13 pages) View the PDF document
Table of Contents
Open this folder and view contentsREGULATORY MATTERS
Open this folder and view contentsSAFETY OF MEDICINES
Open this folder and view contentsPROBLEMS OF CURRENT INTEREST
Open this folder and view contentsFEATURE
 

WHO Pharmaceuticals Newsletter 2005, No. 05

prepared in collaboration with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden

The aim of this Newsletter is to disseminate information on the safety and efficacy of pharmaceutical products, based on information received from our network of "drug information officers" and other sources such as specialized bulletins and journals, as well as partners in WHO. The information is produced in the form of résumés in English, full texts of which may be obtained on request from:

Quality Assurance and Safety:

Medicines, PSM-HTP
World Health Organization,
1211 Geneva 27, Switzerland
E-mail address: pals@who.int

This newsletter is also available on our Internet website: http://www.who.int/medicines

Further information on adverse reactions may be obtained from the WHO Collaborating Centre for International Drug Monitoring, Stora Torget 3, 753 20 Uppsala, Sweden

Tel: 46-18-65.60.60
Fax: 46-18-65.60.80
E-mail: sten.olsson@who-umc.org
Internet:http://www.who-umc.org

News & Issues

This is the last issue for the year 2005 and includes the usual sections on Regulatory Matters and Safety of Medicines. The article on nevirapine under Problems of Current Interest highlights the need to support improved access and use of medicines with matching patient-monitoring facilities. This has been an eventful year in pharmacovigilance. Rofecoxib, withdrawn towards the end of 2004, continued to occupy our interest with many debates and discussions on the lessons learnt and the way forward. Drug safety in children received a lot of attention and several initiatives are underway for establishing guidelines for the safe use of medicines in this vulnerable population. The 'donation' of expired medicines and poor quality devices such as contaminated syringes to tsunami hit regions highlighted the quality and safety issues in drug donation practices, calling attention to the expanding role for pharmacovigilance centres in promoting medicine safety. The year ended with a meeting of the WHO Advisory Committee on Safety of Medicinal Products which reviewed various issues on drug safety; the Committee's recommendations will be published early next year.

© World Health Organization 2005

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

 

to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: November 5, 2014